Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?

This article was originally published in The Pink Sheet Daily

Executive Summary

Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.

You may also be interested in...



Deals Of The Week: Mylan/Biocon, Merck/Lycera, Lilly/Qiagen

A pending regulatory decision in the U.S. and Europe for oncology drug RA 223 and improving sales of AMD drug Eylea, both brought in through partnership activity, may bring some calm to the recently stormy seas traveled by Bayer Healthcare.

Bayer Prices Stivarga With Crowded Colon Cancer Market In Mind

Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.

FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development

A Center for Devices and Radiological Health representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel